This page shows the latest Alector news and features for those working in and with pharma, biotech and healthcare.
One example is US biotech Alector, whose lead candidate AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2) and is based on a view that the disease is caused
Alector is pioneering immuno-neurology, a novel therapeutic that will treat a range of degenerative brain disorders by restoring healthy immune function to the brain. ... Hot on Alector’s heels is Stealth BioTherapeutics, which is aiming to raise $81
Places in J&J's bioincubators have already yielded funding and licensing deals for the likes of Alector, Bell Biosystems and Araxes Pharma.
Alector is targeting key components of the pathological pathways that underlie Alzheimer's using monoclonal antibody technology via its strategic alliance with antibody discovery specialist Adimab. ... This agreement provides Alector with a lot of
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Angus Grant, CEO of the Dementia Discovery Fund, said: “I am delighted that Alector, the first of DDF’s investments, has reached this significant milestone. ... Alector’s progress serves as a great illustration of how the DDF’s investment choices
More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...